- Book
- June 2012
- 596 Pages
- Book
- June 2023
North America
Kawasaki Disease (KD) is an acute, self-limited vasculitis of unknown etiology that primarily affects children under the age of five. It is the leading cause of acquired heart disease in children in developed countries. KD is classified as an allergic and immunologic disorder, and is characterized by fever, rash, conjunctivitis, lymphadenopathy, and changes in the coronary arteries. Treatment of KD includes high-dose intravenous immunoglobulin (IVIG) and aspirin.
KD is a growing market within the allergy and immunology space, with a focus on developing treatments that reduce the risk of coronary artery aneurysms and other long-term complications. Companies in this market are researching and developing novel therapies, such as monoclonal antibodies, to reduce the risk of coronary artery aneurysms and other long-term complications.
Some companies in the Kawasaki Disease market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more